NFKB1 and Miyoshi myopathy: Understanding the interplay between NF-κB signaling, proteasome inhibitors, and other molecular pathways is crucial for developing effective therapeutic strategies for MM patients, with the aim of improving treatment response and reducing the risk of relapse and adverse effects.